ChartMill assigns a Buy % Consensus number of 82% to SNTI. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-21 | Leerink Partners | Initiate | Outperform |
| 2025-10-14 | HC Wainwright & Co. | Initiate | Buy |
| 2025-08-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-06-12 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-06-06 | Laidlaw & Co. | Initiate | Buy |
| 2025-05-02 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-12-04 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-12-02 | Chardan Capital | Maintains | Buy -> Buy |
| 2023-08-15 | Chardan Capital | Reiterate | Buy -> Buy |
| 2023-05-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2023-03-24 | Morgan Stanley | Maintains | Equal-Weight |
| 2023-03-23 | Chardan Capital | Maintains | Buy |
| 2023-01-30 | Chardan Capital | Maintains | Buy |
| 2023-01-27 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-12-16 | JP Morgan | Initiate | Neutral |
| 2022-10-07 | Morgan Stanley | Initiate | Equal-Weight |
| 2022-09-29 | B of A Securities | Initiate | Buy |
| 2022-09-23 | Chardan Capital | Initiate | Buy |
9 analysts have analysed SNTI and the average price target is 13.26 USD. This implies a price increase of 583.51% is expected in the next year compared to the current price of 1.94.
The consensus rating for SENTI BIOSCIENCES INC (SNTI) is 82.2222 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering SENTI BIOSCIENCES INC (SNTI) is 9.